Biotechnology

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates th...

2022-12-21 08:00 2381

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute ofMateria Medica (the "SIMM") and Wuhan Institute of Virology (the "WIV"), Chines...

2022-12-20 19:21 2094

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9M...

2022-12-20 17:00 2301

SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit

First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit...

2022-12-19 21:00 1616

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

HEFEI, China, Dec. 17, 2022 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (Hefei, China), an innovative biotech company dedicated to the discovery of novel immunotherapeutic drugs and a leader in NK cell research globally, today announced that the U.S. Food and Drug Administration (FDA) has cleared i...

2022-12-17 21:30 2833

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Depar...

2022-12-16 08:44 2104

BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

* A leader in creating jobs through the advancement of RNA-based therapeutics * A contributor to a high employment rate in Korea's healthcare industry BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Company"), a RNA therapeutics company with offices in Daejeon, South K...

2022-12-15 21:00 1496

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]  which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...

2022-12-14 21:52 1808

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

2022-12-14 01:40 2125

Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates

Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...

2022-12-13 18:00 1808

Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...

2022-12-13 17:39 1859

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...

2022-12-12 21:50 2228

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...

2022-12-12 21:00 1893

Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...

2022-12-12 20:59 1644

HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company deploying its NITROME platform to buil...

2022-12-12 10:10 1961

Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL)...

2022-12-11 07:15 3683

Shenzhen Holds 2022 Global Investment Promotion Conference to Build a Magnet for International Investors

SHENZHEN, China, Dec. 8, 2022 /PRNewswire/ -- Shenzhen welcomes outstanding investors from all over the world. The 2022 Shenzhen Global Investment Promotion Conference will be held inShenzhen, China on December 9. A number of major projects in the fields of information technology, artificial int...

2022-12-09 11:16 1710

SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...

2022-12-09 06:30 2090

ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit

SAN FRANCISCO, Calif., Dec. 8, 2022 /PRNewswire/ -- ReviR Therapeutics (ReviR), a biotechnology company developing small molecule therapies targeting RNA, today announced an upcoming presentation at the 5th Annual RNA Targeted Drug Discovery conference taking placeDecember 13-15, 2022 in Boston, ...

2022-12-08 23:00 2548

LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been desi...

2022-12-08 22:00 1984
1 ... 61626364656667 ... 127